Boltz’s $110M Round Puts AI Drug Design on Pharma’s Payroll

Human Verified

Share to: , and

A glowing molecular structure and protein helix floating above a laboratory bench with test tubes and a microscope

Boltz, a London AI research lab spun out of MIT, has raised $110 million in Series A funding led by Bessemer Venture Partners. The round will fund more compute and data as the company scales models that design molecules for drug discovery.

The round, and who joined it

All of Boltz’s existing investors doubled down, including Andreessen Horowitz, Amplify Partners, Zetta Venture Partners and Obvious Ventures. New investors Greycroft, F-Prime Capital, Hummingbird and Benchling joined the round, but no valuation was disclosed. The Series A is nearly four times the $28 million seed Boltz announced in January.

Bessemer partner Andrew Hedin and Byron Deeter join Boltz on its journey, bringing deep experience in biotech and AI. The firm says Boltz is building towards programmable molecular design, where scientists specify a molecule and the model delivers it for them.

Models already in paid use

Boltz builds foundation models for biomolecular design: BoltzMol-1 for small molecules and BoltzProt-1 for proteins, released in June behind a consumption-priced API. Its earlier open-source models, Boltz-1 and Boltz-2, are widely used in structure prediction. The company says its models found hits for most of the hard targets it pursued.

The company says it has signed partnerships with six of the world’s 20 largest pharma companies, including Pfizer, GSK, Takeda and Bristol Myers Squibb. Molecular token usage among paying customers has grown 50-fold since June, when the new models launched.

Boltz launched its Boltz Lab platform in January to put its latest models in the hands of any scientist or AI agent. Thousands of scientists signed up within weeks, and the platform now serves pharmaceutical, biotech and industrial companies every day.

The team is 40 people, grown from a small group of MIT researchers in just over a year. Its goal is a world where a scientist can go from a therapeutic hypothesis to a human-ready molecule without leaving the computer.

Boltz plans to invest the new money in compute, data and hiring. Its upcoming models are already showing substantial improvements in the quality of the molecules they generate, according to the company, and demand from partners keeps growing. The funding will also help it meet growing demand from partners.

Our Read

The traction is what makes this round matter. A $110 million Series A is large, but six of the top 20 pharma firms paying by the token is the real signal: Boltz’s models are not demos, they are tools scientists already rely on daily.

The open-source lineage helps too. Boltz gave its early models away, earned trust in the research community, and is now charging for the better models behind an API. That is a cleaner path to revenue than most AI labs manage.

Why It Matters

Drug discovery is one of the clearest places where AI models earn their keep, and pharma’s willingness to pay per token shows the economics are working. If Boltz keeps improving its models, the bottleneck in drug design shifts from computation back to the lab bench.

Background

The round follows a run of large AI funding deals, including Isomorphic Labs’ $5 billion Series C for AI-designed drugs. Boltz’s work sits in the same field, and Claude has also taken on drug discovery work for researchers. The company disclosed no valuation or revenue figures.

Source: Boltz announcement and Bessemer Venture Partners

Share to: , and

Faheem R. Khattak

Senior automation engineer and AI marketing journo covering LLMs, algorithms, analytics, core updates, Bing search, and technical SEO.

0 Comments

Leave a Reply

Optional Take Tag:

🛡️ Spam protection: Honeypot + Time-Trap Active

This site uses Akismet to reduce spam. Learn how your comment data is processed.